3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
Fluorouracil
56
Specimen Handling
51
Oxaliplatin
49
Leucovorin
46
Magnetic Resonance Spectroscopy
45
Bevacizumab
43
Gemcitabine
39
Irinotecan
30
Cetuximab
27
Nivolumab
25
130-nm albumin-bound paclitaxel
25
Cisplatin
24
Biopsy
24
pembrolizumab
22
Paclitaxel
22
Capecitabine
19
atezolizumab
18
durvalumab
14
Taxes
14
Folfox protocol
14
Carboplatin
13
X-Rays
12
Radiotherapy
12
Cyclophosphamide
12
fludarabine
11
dehydroftorafur
10
Radiation
10
Albumin-Bound Paclitaxel
10
Surgical Procedures, Operative
9
Immunoglobulin G
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acetaminophen
×
Gastrointestinal
×
30 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled